Safety and Efficacy of ALX-0600 in Subjects With Active Crohn's Disease Who Completed Protocol CL0600-008

PHASE2CompletedINTERVENTIONAL
Enrollment

67

Participants

Timeline

Start Date

March 1, 2004

Primary Completion Date

November 1, 2005

Study Completion Date

June 1, 2006

Conditions
Crohn's Disease
Interventions
DRUG

Teduglutide (ALX-0600)

0.1 mg/kg injected subcutaneously daily

Trial Locations (24)

10128

Asher Kornbluth, MD, PC, New York

11021

Long Island Clinical Research Associates, Great Neck

20010

Rx Trials, Washington D.C.

23249

McGuire DVAMC, Richmond

27612

Wake Research Associates, Raleigh

30329

Pinnacle Trials, Atlanta

30342

Saint Joseph's Health System, Atlanta

33162

Venture Research, North Miami Beach

33486

Clinical Trials Management of Boca Raton, Boca Raton

33765

Clinical Research of West Florida, Clearwater

40202

University of Louisville, Louisville

44195

Cleveland Clinic Foundation, Cleveland

53715

Dean Foundation Research Center, Madison

60619

Northwestern University School of Medicine, Chicago

60637

University of Chicago, Chicago

73112

Lynn Health Science Institute, Oklahoma City

77005

Atilla Ertan, Houston

80401

Rocky Mountain Gastroenterology, Lakewood

84132

University of Utah, Salt Lake City

85712

Advanced Clinical Therapeutics, Tucson

V5Z 1L5

Vancouver General Hospital, Vancouver

R3A 1R9

Health Sciences Center, Winnipeg

B3H 1V7

Queen Elizabeth II Health Sciences, Halifax

M5S 2A5

Life Screening Centres, Toronto

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Shire

INDUSTRY